The X-linked Plac1 gene is maternally expressed in trophoblast cells during placentation, and its disruption causes placental hyperplasia and intrauterine growth restriction. In contrast, Plac1 is also reported to be one of the upregulated genes in the hyperplastic placenta generated by nuclear transfer. However, the effect of overexpressed Plac1 on placental formation and function remained unaddressed. We complemented the Plac1 knockout placental dysfunction by lentiviral vector-mediated, placenta-specific Plac1 transgene expression. Whereas fetal development and the morphology of maternal blood sinuses in the labyrinth zone improved, placental hyperplasia remained, with an expanded the junctional zone that migrated and encroached into the labyrinth zone. Further experiments revealed that wild-type placenta with transgenically expressed Plac1 resulted in placental hyperplasia without the encroaching of the junctional zone. Our findings suggest that Plac1 is involved in trophoblast cell proliferation, differentiation, and migration. Its proper expression is required for normal placentation and fetal development.
INTRODUCTION
The placenta is a fetomaternal interface that is required for nutrient supply and gas exchange during gestation. The investigation of the function of trophoblast-related genes is important to understand not only placental development but also pregnancy-related diseases. Plac1 is an X-linked gene that is mainly expressed in the trophoblast lineage, such as trophoblast giant cells and labyrinth trophoblast cells in mice [1] . In humans, PLAC1 expression is also restricted to trophoblast cell lineage and enriched specifically in the microvillous membrane surface of the syncytiotrophoblast cells [2, 3] .
Research literature has implicated the importance of PLAC1 in normal placentation. The Xq26 region of the Xchromosome, including CR59647, GPC-3, HPRT, MGC16121, PHF6, and PLAC1, has been implicated in human placental dysplasia, and PLAC1 is the only gene that proved to be specifically expressed in placenta [1] . Downregulation of Plac1 was also reported in hyperplastic placenta associated with interspecific hybrid placental dysplasia (Ihpd) between Mus musculus and Mus spretus [4] [5] [6] . To directly address Plac1 function in vivo, Jackman et al. [7] generated Plac1 disrupted mice and found placental hyperplasia, with the junctional zone encroaching into the labyrinth zone in the conspectuses carrying maternally transmitted mutant Xchromosome. Intrauterine growth restriction and semilethality were observed in these embryos.
By contrast, microarray studies reveal that the Plac1 gene was consistently upregulated in the hyperplastic placenta of a mouse cloned by nuclear transfer (NT) [8] . It is noteworthy that NT-cloned placenta also had an enlarged junctional zone that encroached into labyrinth zone [9] . One possible interpretation is that Plac1 upregulation is caused by placental hyperplasia. Another possibility is that placental hyperplasia might be caused by an overexpression of Plac1.
In the present study, we first analyzed Plac1 expression in preimplantation and postimplantation embryos, then generated Plac1 knockout (KO) mice to examine the gene's importance for embryonic development. Second, we applied the lentiviral (LV) vector-mediated, placenta-specific transgene expression system to complement Plac1 deficiency in KO mice. Finally, to answer the questions mentioned above, we transgenically expressed Plac1 in wild-type (WT) placenta and compared the phenotypes with KO and LV-complemented KO placentas. Our results suggest that the proper expression of Plac1 is required for the normal placentation and fetal development.
MATERIALS AND METHODS

Animals
All animal experiments were approved by the Institutional Animal Care and Use Committee of the Research Institute for Microbial Diseases, Osaka University. The Plac1-deficient mouse line (B6D2F1-Plac1
) and X-linked EGFP mouse line (B6;B6C3-Tg[CAG/Acr-EGFP]CX-FM139Osb) were available to the scientific community through RIKEN BRC (http://www. brc.riken.jp/inf/en/index.shtml).
Reverse Transcription-Polymerase Chain Reaction
Mouse cDNA was prepared from blastocyst (Embryonic Day 3.5 [E3.5]) and early gestational-to midgestational-stage embryos (E6.5;E7.5). The RT-PCR was performed using 10 ng of cDNA and the following primers: 5 0 -ATGAACCTTCGCAAGTTCCTGGG-3 0 and 5 0 -TTACATGCTCTTTT GATTGTAGACATAAGGTGG-3 0 for Plac1, 5 0 -AAGTGTGACGTTGA CATCCG-3 0 and 5 0 -GATCCACATCTGCTGGAAGG-3 0 for beta actin (bactin), and 5 0 -ATCCTCTGCATGGTCAGGTC-3 0 and 5 0 -CGTGGCCTGATT CATTCC-3 0 for lacZ. [10] . The amplification cycles were 948C for 30 sec, 658C for 30 sec, and 728C for 30 sec, with a final 2 min of extension at 728C.
Quantitative RT-PCR
Mouse cDNA was prepared from blastocyst (E3.5) and placenta (E16.5). Each cDNA was subjected to quantitative RT-PCR analysis with a Thermal Cycler Dice TP800 (Takara-Bio) using SYBR Premix Ex Taq II RR820S (Takara-Bio). The relative expression level of each target gene mRNA was normalized to the amount of b-actin control. Each reaction was performed in duplicate, and data are presented as the mean plus SD. Primer sets were as follows: 5 0 -GCGTTACCGAATGTGGCATC-3 0 and 5 0 -CAGCTG CAGTTGGGTTGTTC-3 0 for Plac1, and 5 0 -AAGTGTGACGTTGA CATCCG-3 0 and 5 0 -GATCCACATCTGCTGGAAGG-3 0 for b-actin.
Generation of Plac1 Gene-Deficient Mice
Plac1 gene-targeting vector (DPGS00170_A_E06) was purchased from the International Knockout Mouse Consortium (IKMC). After linearization with AsiSI digestion, the targeting vector was electroporated into EGR-G101 embryonic stem (ES) cells [11] . After positive (G418) and negative (DT) selection, among the 48 drug-resistant clones 14 clones were identified as homologous recombinant clones by PCR screening with primers 5 
Blastocyst Collection and Sex Determination
Female mice were superovulated by i.p. injection of a pregnant mare's serum gonadotropin (5 units) followed by human chorionic gonadotropin (5 units) 48 h later, and then they were mated with male mice. Two-cell-stage embryos were collected from the females at 1.5 days after copulation and then incubated in KSOM medium for 2 days to obtain blastocysts. For gender selection, the blastocysts collected from WT female mice mated with X egfp Y (B6;B6C3-Tg[CAG/Acr-EGFP]CX-FM139Osb) male mice were separated into male (EGFP-negative) and female (EGFP-positive) blastocysts under a fluorescence stereomicroscope [12] . The RNA collected from these genderspecific blastocysts was pooled and subjected to RT-PCR for Plac1 expression analysis. For genotyping experiments, each blastocyst was placed in 20 ll of lysis buffer (20 mM Tris-HCl [pH 8.0], 5 mM ethylene diamine tetraacetic acid, 400 mM NaCl, SDS 0.3%, and 200 lg/ml Proteinase K), and 0.5 ll was subjected to PCR analysis. Plac1 genotype was performed with the abovementioned primers, and Ube1X primers 5 0 -TGGTCTGGACC CAAACGCTGTCCACA-3 0 and 5 0 -GGCAGCAGCCATCACATAATCCA GATG-3 0 were used for sexing [13] .
Tissue Preparation and Histological Analysis
At E3.5 through E16.5, the pregnant mice were killed, and their uteri were dissected to collect embryonic or extraembryonic tissues. For embryos at E6.5 through E9.5, the uteri were removed and conceptuses were used for RT-PCR. For embryos at E12.5 through E16.5, the uteri were removed and individual fetuses were dissected from the uterus with embryonic membranes intact. Placentas were fixed in 4% paraformaldehyde in PBS and were processed for paraffin embedding or frozen section. The 5-lm paraffin sections were stained with periodic acid-Schiff (PAS) and then counterstained with Mayer hematoxylin solution (Wako). The 10-lm frozen sections were stained with X-Gal to detect b-galactosidase (b-gal) activity (LacZ Tissue Staining Kit; InvivoGen), then counterstained with 0.3% eosin for 2 min, rinsed in 70% ethanol, dehydrated in increasing ethanol concentrations, and finally mounted in Entellan new (Merck).
Immunohistochemical Analysis
The sliced sections were incubated with 1% bovine serum albumin in PBS for 1 h to block nonspecific reactions. These were then incubated overnight with the following primary antibodies: anti-Laminin antibody (no. L9393; Sigma-Aldrich) to stain the endothelial basement membrane of fetal capillaries [14] , and anti-Ki67 antibody (no. 12202; Cell Signaling Technology) to stain the proliferating cells. After incubation with secondary antibodies conjugated with horseradish peroxidase, we used diaminobenzidine tetrahydrochloride (DAB; Nacalai Tesque) to stain the sliced sections with a hematoxylin counterstain.
Morphometric Quantification of Placenta
The centerlines of each of the maternal blood sinuses in the labyrinth zone of the placenta were manually selected, and the widths were measured. We analyzed 20 sinuses in 3 areas for 3 placentas per group. Each placental layer was manually selected, and the areas were measured. We analyzed three placentas per group. The images were analyzed with ImageJ software (National Institutes of Health).
Preparation of Lentiviral Vectors
The HIV-1-based, self-inactivating lentiviral vector plasmid pLV-EGFP was described previously [15] . Mouse Plac1 cDNA was amplified by RT-PCR using placental tissue with primers 5
0 . A 0.5-kb XbaI-EcoRI Plac1 fragment was inserted into lentiviral vector plasmid under the CAG promoter (pLV-Plac1). The pLV-Plac1 plasmid was transfected to 293T cells by the calcium phosphate method. Lentiviral vectors were harvested 2 days after transfection, and then they were concentrated 1000 times by ultracentrifugation (19 400 rpm, 2 h; 21 000 rpm, 2 h). After resuspension with Hanks Balanced Salt Solution buffer, the lentiviral vector concentration was determined by measuring p24 gag antigens by ELISA [15] .
Lentiviral Transduction for Mouse Blastocysts
Blastocysts were collected as described above. To remove the zona pellucida, the blastocysts were incubated in acidic Tyrode solution (SigmaAldrich) for 30-60 sec and washed three times in KSOM. Prepared zona pellucida-free blastocysts were incubated individually for 4 h in medium containing lentiviral vectors. LV-EGFP and LV-Plac1 were used at 1000 ng of p24 per milliliter. The transduced blastocysts were implanted into the uteri of pseudopregnant E2.5 ICR female mice. We transplanted 10 blastocysts into each horn of the uterus.
Statistical Analysis
All values are shown as the mean 6 SD of at least three independent experiments. Statistical analyses were performed using Student t-test inserted in Excel after the data were tested for normality of distribution.
RESULTS
Allele-Specific Expression of Plac1 Gene
Whereas maternally imprinted Plac1 expresses after implantation and Plac1 KO mice tend to succumb somewhere between late gestation and weaning [7] , Plac1 expression and its physiological role have not been examined in preimplantation embryos. Thus, we examined Plac1 expression in blastocyst-stage embryos. When we mated WT female mice with transgenic male mice carrying the EGFP-expressing transgene on the X chromosome (X egfp ) [12] , blastocysts could be separated into fluorescent female blastocysts (XX egfp ) and nonfluorescent male blastocysts (XY) under a fluorescent stereomicroscope. By RT-PCR, we found that Plac1 expression in female blastocysts was higher than in the male blastocysts, indicating paternally imprinted gene expression (Fig. 1, A and B) . Soon after implantation, maternal Plac1 started expression, and both sexes of embryos expressed equivalent amounts of Plac1, implicating silencing of paternal Plac1 expression (Fig. 1, A and B).
Generation of Plac1 Mutant Mice
To characterize Plac1 gene expression and its function, we generated Plac1 mutant mice with the gene-targeting MUTO ET AL. vector designed by IKMC (Supplemental Fig. S1A ; Supplemental Data are available online at www.biolreprod.org). The ORF region was replaced with a lacZ reporter transgene to visualize Plac1 gene expression and disrupt Plac1 gene function simultaneously. We confirmed the homologous recombination in ES cells and germ line transmission by PCR analysis (Supplemental Fig. S1B ). Whereas LacZ expression in the X p-X blastocyst was observed, Plac1 expression in the X p-X blastocyst was lower than in the control XX blastocyst (Supplemental Fig. S1C ). When we stained the placenta with X-gal at E11.5, LacZ-positive cells appeared only in the placenta carrying the maternally transmitted mutant allele. Positive cells were mainly distributed in the junctional zone, and some were in the labyrinth zone (Supplemental Fig. S1D ). At E14.5, LacZpositive signals were strongly detected in the encroached junctional zone (Supplemental Fig. S1E ). The expression of Plac1 from the maternally inherited allele during placentation was consistent with previous reports [7] .
Plac1 Deficiency and Preimplantation Development
To determine whether paternally expressed Plac1 plays an important role during preimplantation development, we collected and genotyped blastocysts from WT XX females mated with Plac1 mutant X -Y males, and Plac1 mutant X -X females mated with WT XY males. In either combination, the expected number of blastocysts carrying Plac1 mutant allele PLACENTAL HYPERPLASIA IN Plac1 GENE-MODIFIED MICE was obtained (Fig. 1C ). There were no morphological or developmental abnormalities observed in the mutant blastocysts (data not shown). These results indicate that the Plac1 gene is not required for preimplantation embryonic development.
Plac1 Deficiency and Postimplantation Development
To evaluate the effect of Plac1 deficiency in postimplantation development, Plac1 mutant female mice were mated with mutant male mice as shown in Figure 1D . Whereas the intercrossing with Plac1 XX female and X -Y male mice showed normal litter size (number of pups: X p-X, 5.5 6 1.7; XY, 3.8 6 1.3; litter size, 9.3 6 1.5; n ¼ 30), Plac1 mutant females (X -X) showed a decreased litter size, with reduced numbers of the maternally mutated embryos (X -X 3 XY mating: number of pups: XX, 2. Fig. 1D ). We analyzed the proportion of embryos produced by the cross between X -X females and XY males in midgestational stages (E11.5;E14.5; n ¼ 15) through late-gestational stages (E15.5;E17.5; n ¼ 6). Although the number of WT embryos was comparable (midgestation, 3.9 6 1.0; late gestation, 3.7 6 2.3; P ¼ 0.7813), X mmutant embryos tended to decrease during late-gestational stages (midgestation: X m-mutant, 4.7 6 1.8; late-gestation: X mmutant, 3.0 6 1.3; P ¼ 0.0494). These results reconfirmed that maternally expressed PLAC1 protein plays an important role in postimplantation embryonic development [7] . Notably, the intercrossing with Plac1 X -X -and X -Y mice gave 3.7 times more maternally mutated pups (number of pups: X m-Y, 1.1 6 0.7; X m-X p-, 3.3 6 1.5; litter size, 4.4 6 1.9; n ¼ 18) than heterozygous intercrosses (maternally mutated pups, 1.2 6 0.96 in X -X 3 XY and 1.2 6 0.86 in X -X 3 X -Y mating; Fig. 1D ).
Placental Hyperplasia and Intrauterine Growth Restriction in Plac1 Mutant Mice
To understand when the defects appear during gestation, we weighed fetuses and placentas obtained from the intercrossing of Plac1 X -X female with XY male mice at the indicated embryonic days (Supplemental Fig. S2, A and B) . Placentas carrying the X m-mutation showed weights comparable with those of WT placentas (WT, 70 6 23 mg; n ¼ 14; X m-, 83 6 37 mg; n ¼ 12) at E12.5, then significantly increased their weight during midgestation (E14.5: WT, 104 6 18 mg; n ¼ 16; X m-, 190 6 33 mg; n ¼ 20; E16.5: WT, 86 6 21 mg; n ¼ 16; X m-, 203 6 55 mg; n ¼ 12; Supplemental Fig. S2A ). Whereas X m-mutated fetal weight was comparable with that of the WT fetus during E12.5 through E14.5, X m-mutated fetal weight was lower than that of the WT fetus at E16.5 (E12.5: WT, 83 6 12 mg; n ¼ 14; X m-, 70 6 23 mg; n ¼ 12; E14.5: WT, 267 6 42 mg; n ¼ 16; X m-, 246 6 38 mg; n ¼ 20; E16.5: WT, 770 6 52 mg; n ¼ 16; X m-, 670 6 119 mg; n ¼ 12; Supplemental Fig. S2B ).
Histological Analysis of Plac1 Mutant Placentas
We then performed the histological analysis of Plac1 mutant placentas by PAS staining, which detects polysaccharides, such as glycogen and mucosubstances, such as glycoproteins, glycolipids, and mucins. Whereas no apparent abnormality was found in maternally Plac1 mutated (X m-) placentas at E12.5 (Supplemental Fig. S2C ), mutant placentas showed overgrowth with an expanded junctional zone that encroached into the labyrinth zone at E13.5 ( Fig. 2A) . No overt developmental abnormalities were found in paternally Plac1 mutated (X p-) placentas ( Fig. 2A) . Whereas the areas of the decidua and labyrinth zone showed no difference among WT, X p-, and X m-placentas, the area of the junctional zone significantly increased in the X m-placenta (Fig. 2B) . When we stained placentas with anti-Ki67 (cell proliferation marker) antibody, more signals were observed in the junctional zone of the X m-placenta (Supplemental Fig. S3 ). It is noteworthy that morphological abnormalities appeared in the X m-mutant placental labyrinth zone by laminin immunostaining (Fig.  2C) . Although the fetal blood vessel formation of X m-mutant placenta was observed, adjacent maternal blood sinuses were dilated (Fig. 2, C and D) .
Transgenic Complementation of Plac1 Deficiency Using Lentiviral Vectors
To confirm that PLAC1 deficiency is the principal cause of the phenotype, we restored Plac1 expression by using lentiviral (LV) vector-mediated, placenta-specific gene expression system [15] . Blastocysts collected from Plac1 X -X females mated with WT male mice were transduced with the LV vectors expressing PLAC1 (LV-Plac1) and transplanted into pseudopregnant mice (Fig. 3A) . Placenta-specific genomic integration of the LV-Plac1 was confirmed by PCR (Fig. 3B) . When we compared the amount of Plac1 mRNA by quantitative RT-PCR, LV-Plac1-transduced X m-mutant placentas showed about five times more Plac1 mRNA than LV-EGFP-transduced WT placenta (Supplemental Fig. S4 ). When we transduced the maternally Plac1-mutated blastocysts (X m-X and X m-Y) with LV-Plac1, the proportion was improved compared with that of the control LV-EGFP (X m-mutant pups ratio was 40.4% with LV-Plac1 compared with 22.9% with control LV-EGFP; Fig. 3C ). The fetal body weight of LVPlac1-transduced mutant placentas was also improved (LV-EGFP-treated X m-mutant: 649 6 128 mg; n ¼ 19; LV-Plac1-treated X m-mutant: 740 6 88 mg; n ¼ 21; Fig. 3D, right) . Unexpectedly, LV-Plac1-transduced mutant placentas remained hyperplastic (LV-EGFP-treated X m-mutant: 202 6 55 mg; n ¼ 12; LV-Plac1-treated X m-mutant: 276 6 74 mg; n ¼ 15; Fig. 3D, left) . Histological analysis revealed that dilation of maternal blood sinuses in the labyrinth zone was improved, although the hyperplastic junctional zone remained (Fig. 3, E and F) .
LV-Plac1 Transduction in WT Placentas
Whereas Plac1 deficiency caused placental hyperplasia, overexpression of Plac1 was also reported in hyperplastic placentas from the NT-cloned mouse [8] . Therefore, we transduced LV-Plac1 in WT placentas to examine its function. There was no difference in fetal development ability when we observed at E16.5 (live fetuses:transplanted blastocysts were 15:40 [37%] and 14:40 [35%] with LV-EGFP and LV-Plac1, respectively). Placental weight significantly increased in the LV-Plac1 treated group (LV-EGFPtreated WT placenta: 85.6 6 21 mg; n ¼ 16; LV-Plac1-treated WT placenta: 129 6 27.5 mg; n ¼ 24; Fig. 4A ). Although the fetal weight of the LV-Plac1-treated group tended to be smaller than that of the LV-EGFP-treated controls (LV-EGFP-treated WT fetus: 770 6 51.9 mg; n ¼ 16; LV-Plac1-treated WT fetus: 732 6 65 mg; n ¼ 24; Fig. 4B ), it was not significant (P ¼ 0.055). Histological analysis revealed that the LV-Plac1-transduced labyrinth zone did not show the dilation MUTO ET AL.
FIG. 2. Histological analysis of hyperplastic placenta in
Plac1 X m-mice. A) PAS staining of placenta. At E13.5, Plac1 X m-placenta showed hyperplasia, expanded the junctional zone, and showed morphological abnormalities in the labyrinth zone. Plac1 X p-placenta was normally formed. The enlargements of the leftmost images are shown in the middle images, and the enlargements of the middle images are shown in the rightmost images. Bars ¼ 1 mm (left), 200 lm (center), and 50 lm (right). B) Morphometric analysis of placenta. The area of the junctional zone significantly increased in X mmutant placenta at E13.5 (n ¼ 3 per group; *P , 0.05, **P , 0.01, ***P , 0.001; n.s., no significant difference). C) Laminin immunohistochemistry of placenta (DAB staining). Whereas fetal capillaries in the labyrinth zone were observed, neighboring maternal blood sinuses were dilated in Plac1 Y blastocysts were collected from Plac1 X -X mothers. Zona pellucida-free blastocysts were transduced with a lentiviral vector expressing Plac1 (LV-Plac1) and were transplanted into pseudopregnant females. Primers A (5 0 -GCAACGTGCTGGTTGTTGTGCTGTCTCATC-3 0 ) and B (5 0 -TTACATGCTCTTTTGATTGTAGACATAAGGTGG-3 0 ) were used to detect LV-Plac1 transgene. B) Placenta-specific Plac1 transgene integration. Genomic DNA was extracted from fetuses or placentas at E17.5 and subjected to PCR analysis using the MUTO ET AL. C) The proportion of Plac1 mutant pups after LV-Plac1 transduction. The pups developed from the LVPlac1-transduced blastocysts were genotyped by PCR at birth. D) The placental and fetal body weights of Plac1 X m-mutant mice at E16.5. The fetuses developed from LV-Plac1-transduced mutant blastocysts were larger than those of the LV-EGFP control. The LV-Plac1-transduced mutant placenta remained hyperplastic (*P , 0.05, **P , 0.01). We present the placental weight and fetal body weight of WT controls in Figure 4 , A and B (LV-EGFPtreated WT placenta, 85.6 6 21 mg; n ¼ 16; LV-EGFP-treated WT fetus, 770 6 51.9 mg; n ¼ 16). E) PAS staining and laminin immunostaining (DAB staining) of LV-transduced placenta at E16.5. Hyperplastic junctional zone that encroached into the labyrinth zone was observed. The laminin immunostaining shows that fetal capillaries and maternal blood sinus were formed normally in LV-Plac1 complemented placenta. Bars ¼ 1 mm, 200 lm, 50 lm, and 50 lm, respectively from the left. F) Width of maternal blood sinus in the labyrinth zone of E16.5 LV-treated Plac1 X m-mutant placenta (n ¼ 180 from 3 placenta per group; ***P , 0.001). Dilation of maternal blood sinuses was restored in LV-Plac1-transduced X m-mutant placenta.
FIG. 4. LV-Plac1 transduction of WT placenta resulted in hyperplasia.
A) The placental weight of LV-Plac1-transduced WT embryos at E16.5. LV-Plac1-treated placentas were larger than those in the LV-EGFP-treated group (***P , 0.001). B) The fetal weight of LV-Plac1-transduced WT embryos at E16.5. There was no significant difference between the two groups. C) Histological analysis by PAS staining and laminin immunostaining of LV-Plac1-transduced WT placentas at E16.5. There was no apparent abnormality in the junctional and labyrinth zones. Bars ¼ 1 mm, 200 lm, 50 lm, and 50 lm, respectively from the left. D) Morphometric analysis of placenta. The area of junctional and labyrinth zones significantly increased in LV-Plac1-transduced WT placentas at E16.5 (n ¼ 3 per group; *P , 0.05). n.s., no significant difference.
PLACENTAL HYPERPLASIA IN Plac1 GENE-MODIFIED MICE of maternal blood sinus that was observed in Plac1 KO placenta (Fig. 4C ). In addition, the areas of the junctional and labyrinth zones significantly increased in LV-Plac1-transduced placentas (Fig. 4D) .
DISCUSSION
Plac1 is an X-chromosome-linked and reported to be maternally expressed gene that plays important roles in both placental and embryonic development [7] . In the present study, by separating male and female blastocysts using an X egfp transgenic strain, we demonstrated that Plac1 gene is paternally expressed before implantation and then switched to be maternally expressed after implantation. Recently, transient imprinting and aberrant allele switching have been implicated in developmental and disease-related phenotypes [16, 17] . For example, during mammalian development, many loci maintain parent-of-origin DNA methylation only briefly after fertilization [16] . Antisense noncoding RNA has also been implicated in the imprint switch mechanism in breast cancers [17] . Because Gm35988 is listed as intragenic lincRNA from the Plac1 locus, it may play a role in both preimplantation and postimplantation gene expression. Although Plac1 is not essential for preimplantation development, further studies might elucidate the transition mechanism of gene expression and its physiological functions.
After implantation, Plac1 is maternally expressed, and its disruption causes impaired placentation and subsequent fatal problems in embryos [7] . In the present study, we also confirmed that maternal Plac1 deficiency causes fatality during pregnancy. Unexpectedly, more than twice as many maternally mutated pups were obtained from the intercrossing with Plac1 X -X -and X -Y mice compared with those obtained from heterozygous intercrosses (Fig. 1D) . Because all of the offspring from the X -X -3 X -Y cross became Plac1 null mice, the possibility of Plac1 reactivation can be ruled out. In general, litter size and fetal body size are usually inversely correlated. Because the litter size from the X -X -and the X -Y cross was reduced, we assumed that the embryos received more nutrients from the mother. In other words, placental functions are more critical for fetal development in competitive circumstances.
Notably, there are some similarities and differences among WT placenta, Plac1 mutant placenta, LV-Plac1 complemented mutant placenta, and LV-Plac1 transduced WT placenta (Fig.  5) . From the histological analysis, we observed defects in Plac1 mutant placenta: the encroaching junctional zone, and the morphological impairment of maternal blood sinuses in the labyrinth zone. Lentiviral vector-mediated, placenta-specific Plac1 expression restored the morphology of labyrinth zone but not the placental hyperplasia with the encroaching junctional zone. With the recent report that Plac1 is also expressed in the fetus proper [18] , the contribution of fetal Plac1 expression should be taken into account for placental size regulation and compartmentation of placental layers. This is also supported by work in which WT tetraploid complementation could not restore the placental phenotypes of NTcloned mice [19] .
Although the Plac1 gene is upregulated in NT-cloned placentas, Plac1-deficient placentas showed phenotypes similar to NT-cloned placentas. We transduced LV-Plac1 in placentas specifically in WT embryos. Unexpectedly, these placentas showed hyperplasia with normal junctional and labyrinth zone formation. The expression level of the Plac1 transgene is approximately five times greater than that of the endogenous gene, implicating that Plac1 overexpression caused the placental hyperplasia. Because LV-Plac1-treated KO and WT placentas showed comparable amounts of Plac1 mRNA in the placenta (five times more than endogenous level), the histological difference observed in these placentas may be attributed to the difference in fetal Plac1 expression. With the fact that NT-cloned placental defects were normalized with WT fetus [19] , our results reinforce the importance of fetal Plac1 expression for normal placentation.
In summary, we used gene knockout mice and a lentiviral vector-mediated, placenta-specific gene expression system to elucidate the Plac1 function in vivo. Our findings demonstrate the importance of the fine tuning of Plac1 expression for proper formation of the junctional and labyrinth zones. These findings augment our limited knowledge of how Plac1 gene expression is developmentally regulated and how it influences placental formation and functions. In addition, our results further support prior work showing the critical importance of the fetoplacental proportion in determining total intrauterine growth.
